SCHEMBL3014222

SCHEMBL3014222

COc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4ccc(Cl)cc4)CC3)n2)cc1OC

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.43
ALDH1A1 P00352 2/20 0.43
GAA P10253 1/20 0.42
POLB P06746 1/20 0.39
MAPK1 P28482 1/20 0.38
SMPD3 Q9NY59 1/20 0.38
KDM4E B2RXH2 3/20 0.37
HTR7 P34969 1/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
RAB9A P51151 3/20 0.37
NPC1 O15118 1/20 0.37
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
TP53 P04637 1/20 0.36
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
ACHE P22303 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017082 0.95 GAA (0.40) MAPTALDH1A1GAAPOLBMAPK1
SCHEMBL3004189 0.94 MAPT (0.38) MAPTALDH1A1GAAPOLBKDM4E
SCHEMBL3014450 0.93 KDM4E (0.41) MAPTALDH1A1KDM4ESMN1; SMN2RAB9A
SCHEMBL3016776 0.92 SMN1; SMN2 (0.39) MAPTALDH1A1POLBSMPD3KDM4E
SCHEMBL3007183 0.91 ERBB2 (0.39) MAPTALDH1A1GAAKDM4EHTR7
SCHEMBL3013502 0.91 SMN1; SMN2 (0.39) MAPTALDH1A1GAAPOLBKDM4E
SCHEMBL3012971 0.91 SMN1; SMN2 (0.41) MAPTALDH1A1POLBMAPK1KDM4E
SCHEMBL3022985 0.91 KDM4E (0.37) MAPTALDH1A1KDM4ESMN1; SMN2RAB9A
SCHEMBL3011419 0.91 MAPT (0.40) MAPTALDH1A1GAAMAPK1SMN1; SMN2
SCHEMBL3014002 0.91 ALDH1A1 (0.38) MAPTALDH1A1GAAKDM4EHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885ALDH1A1 3510/4885GAA 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.